Attendance is limited, so please register early



Advances in genomics, transcriptomics and sequencing technologies have contributed immensely to discovering molecular alterations that develop into potential biomarkers and therapeutic targets. But how do we know whether these alterations play a causal role in a particular phenotype or disease? We test it by modulating gene activation, repression, expression or even inserting a candidate mutation. 


With the advent of large-scale gene editing technologies, especially those using CRISPR/Cas9, a specific set of genes of interest, or even an entire genome, can be modulated at once in a population of cells. This strategy has been very successful for understanding gene function and uncovering cellular dependencies. 


This course is free of charge and open to graduate students, post-docs, and other participants interested in learning how to perform CRISPR/Cas9-based screens in mammalian cells.

* It is not about learning how to modulate one gene of interest in a cell model. It's about learning how to modulate several genes at once to find out which one is your gene of interest. 


  • Concepts of CRISPR/Cas9 and available tools and applications

  • Using CRISPR/Cas9 for drug discovery

  • Design of target specific CRISPR/Cas9 tools

  • Confirmation and validation of genome-edited cell

  • Concepts of CRISPR/Cas9 screens and applications

  • Designing and performing a CRISPR/Cas9 screen

  • Bioinformatics strategies to analyse CRISPR/Cas9 screen data

  • Strategies for screen validation 

  • Limitations of CRISPR-based screens, strategies to troubleshoot experimental steps


This virtual course will take place between the 15th and 17th of September, starting at 10:00 am (GMT-3/Brasilia).

We will use Zoom for the lectures and discussions, and Slack for instant messaging of instructors and participants. 

The course lectures will be followed by discussions between participants and instructors and will be presented live.

Some material will be recorded but participants must be available to attend sessions at these times.


On Day 1, we will have three lectures by renewed scientists with extensive experience in the field covering topics from the basics of CRISPR/Cas9 strategies to how to use CRISPR for drug discovery.


On the second and third days, participants will learn how to design, execute, analyse and validate a pooled CRISPR/Cas9 screen. Important technical knowledge of all steps will be discussed, including limitations, strategies for troubleshooting experimental steps, and quality control of the reagents, libraries and datasets.


At the end of the course, participants will have the opportunity to discuss in detail a specific idea or example of CRISPR/Cas9 screens with the instructors. This workshop will be offered to a limited number of participants, preferably those who attend the full course, are familiar with CRISPR/Cas9 strategies and plan to perform a screening in the short term. Please let us know whether you are interested in the registration form.



10:00-11:00 (GMT-3/Brasilia)

Applications of CRISPR technology for Genetic Screens 

John Doench, Broad Institute of MIT and Harvard, USA.

11:00-12:00 (GMT-3/Brasilia)

Next-generation genome editing technologies

Holly Rees, Beam Therapeutics, UK.

12:00-13:00 (GMT-3/Brasilia)

Using CRISPR to find tomorrow’s drug targets in cancer

Ultan McDermott, Astrazeneca, UK.



10:00-11:00 (GMT-3/Brasilia)

A Practical Guide to CRISPR Screening

Victoria Harle, Wellcome Trust Sanger Institute

11:00-12:00 (GMT-3/Brasilia)

A Practical Guide to CRISPR screen analysis

Victoria Offord, Wellcome Trust Sanger Institute

12:00-13:00 (GMT-3/Brasilia)

So you’ve done your CRISPR screen now what?

David Adams, Wellcome Trust Sanger Institute



10:00-10:30 (GMT-3/Brasilia)

Genome-wide CRISPR screen identifying human SIN3B synthetic lethal targets

Larissa S. A. S. Matsuyama, University of Sao Paulo, Brazil

10:30-11:00 (GMT-3/Brasilia)

CRISPR activation screen in mice identifies novel membrane proteins enhancing pulmonary metastatic colonisation

Louise van der Weyden, Wellcome Trust Sanger Institute

11:00-11:30 (GMT-3/Brasilia)

In vivo screen identifies calcium signaling as a determinant of T cell sensitivity in melanoma.

Juliana Kenski, The Netherlands Cancer Institute

11:30-13:00 (GMT-3/Brasilia)
Lunch Break

13:00-15:00 (GMT-3/Brasilia)

Project-focused discussion workshop




John Doench 

Director of research and development in the Genetic Perturbation Platform and institute scientist

Broad Institute of MIT and Harvard, USA. 

Holly Rees 

Senior Scientist

Beam Therapeutics, USA 

Ultan McDermott

Chief Scientist in Oncology R&D and Honorary Faculty

AstraZeneca and Wellcome Sanger Institute, UK.

Victoria Harle

Postdoctoral Fellow

Wellcome Sanger Institute, UK. 

Victoria Offord

Principal Bioinformatician

Wellcome Sanger Institute, UK.

David Adams

Senior Group Leader and Head of Experimental Cancer Genetics

Wellcome Sanger Institute, UK. 


Louise van der Weyden

Senior Staff Scientist

Wellcome Sanger Institute, UK.

Larissa S. A. S. Matsuyama

PhD Student

University of Sao Paulo, Brazil

Juliana Kenski

PhD Student

Netherlands Cancer Institute, The Netherlands. 



REGISTER BY clicking On the bellow buttom:

Registration guidelines:

  1. Attendance is limited, so please register as soon as possible to secure your spot.

  2. Participants will be directed to a form by clicking on the registration link. 

  3. You can choose to attend specific sessions or the full course.

  4. If you plan to participate in the project focused-discussion workshop, please select participation in all sessions.

  5. For those interested in the workshop, please take your time to describe (at the end of the form) why you are interested and what question or project you would like to answer with a screen.

you may contact us at:


Organizing Committee:


Patricia A. Possik                    David Adams